TipRanks
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
Germany Market
9IP1
Rocket Pharmaceuticals
RESEARCH TOOLSreports

Rocket Pharmaceuticals (9IP1) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

9IP1 Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
7 Buy
4 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Rocket
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9IP1 Stock 12 Month Forecast

Average Price Target

€8.48
▲(188.30% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is €8.48 with a high forecast of €13.38 and a low forecast of €3.57. The average price target represents a 188.30% change from the last price of €2.94.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","14":"€14","4.25":"€4.25","7.5":"€7.5","10.75":"€10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.3832976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.47608848,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.56887936,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.25,7.5,10.75,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.38,3.2264075076923078,4.072815015384615,4.919222523076923,5.7656300307692305,6.612037538461538,7.458445046153845,8.304852553846153,9.151260061538462,9.997667569230769,10.844075076923076,11.690482584615385,12.53689009230769,{"y":13.3832976,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.38,2.8489298830769227,3.317859766153846,3.7867896492307693,4.255719532307692,4.724649415384615,5.193579298461538,5.662509181538462,6.1314390646153845,6.600368947692307,7.06929883076923,7.538228713846154,8.007158596923077,{"y":8.47608848,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.38,2.471452258461538,2.562904516923077,2.654356775384615,2.745809033846154,2.837261292307692,2.928713550769231,3.020165809230769,3.1116180676923078,3.203070326153846,3.2945225846153847,3.385974843076923,3.4774271015384617,{"y":3.56887936,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.542,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.973,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.707,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.754,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.717,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.167,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.879,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€13.38Average Price Target€8.48Lowest Price Target€3.57
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on DE:9IP1
Richard Law CFA
Goldman Sachs
Goldman Sachs
€2.68→€3.57
Hold
21.39%
Upside
Upgraded
10/08/26
Rocket Pharmaceuticals upgraded to Neutral from Sell at Goldman SachsRocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
Bank of America Securities Analyst forecast on DE:9IP1
Jason Zemansky
Bank of America Securities
Bank of America Securities
€8.92
Buy
203.48%
Upside
Reiterated
10/07/26
Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
Canaccord Genuity Analyst forecast on DE:9IP1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€8.92
Buy
203.48%
Upside
Reiterated
10/07/26
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)
Needham Analyst forecast on DE:9IP1
Gil Blum
Needham
Needham
€8.03
Buy
173.13%
Upside
Reiterated
10/07/26
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT) and Chemed (NYSE: CHE)
Morgan Stanley Analyst forecast on DE:9IP1
Michael Ulz
Morgan Stanley
Morgan Stanley
€4.46
Hold
51.74%
Upside
Reiterated
10/07/26
Analyst Maintains Hold Rating and $5 Price Target on Rocket Despite Long‑Term Danon Potential and Execution Risks
Leerink Partners Analyst forecast on DE:9IP1
Mani Foroohar
Leerink Partners
Leerink Partners
€6.25→€3.57
Hold
21.39%
Upside
Reiterated
10/07/26
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (NASDAQ: RCKT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Wedbush Analyst forecast on DE:9IP1
Yun Zhong
Wedbush
Wedbush
€13.38
Buy
355.21%
Upside
Reiterated
10/07/26
Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)
Cantor Fitzgerald Analyst forecast on DE:9IP1
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
€13.38
Buy
355.21%
Upside
Reiterated
10/06/26
Cantor Fitzgerald Remains a Buy on Rocket Pharmaceuticals (RCKT)
LifeSci Capital Analyst forecast on DE:9IP1
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€10.71
Buy
264.17%
Upside
Reiterated
10/02/26
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Chardan Capital Analyst forecast on DE:9IP1
Keay Nakae
Chardan Capital
Chardan Capital
€9.81
Buy
233.82%
Upside
Reiterated
09/15/26
Chardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
TD Cowen Analyst forecast on DE:9IP1
Tara Bancroft
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX) and Rocket Pharmaceuticals (NASDAQ: RCKT)
J.P. Morgan Analyst forecast on DE:9IP1
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
04/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (NASDAQ: RCKT) and Moderna (NASDAQ: MRNA)
Evercore ISI Analyst forecast on DE:9IP1
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€4.46
Hold
51.74%
Upside
Reiterated
12/17/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (NASDAQ: INSM), Novan (NASDAQ: NOVN) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on DE:9IP1
Richard Law CFA
Goldman Sachs
Goldman Sachs
€2.68→€3.57
Hold
21.39%
Upside
Upgraded
10/08/26
Rocket Pharmaceuticals upgraded to Neutral from Sell at Goldman SachsRocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
Bank of America Securities Analyst forecast on DE:9IP1
Jason Zemansky
Bank of America Securities
Bank of America Securities
€8.92
Buy
203.48%
Upside
Reiterated
10/07/26
Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
Canaccord Genuity Analyst forecast on DE:9IP1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€8.92
Buy
203.48%
Upside
Reiterated
10/07/26
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)
Needham Analyst forecast on DE:9IP1
Gil Blum
Needham
Needham
€8.03
Buy
173.13%
Upside
Reiterated
10/07/26
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT) and Chemed (NYSE: CHE)
Morgan Stanley Analyst forecast on DE:9IP1
Michael Ulz
Morgan Stanley
Morgan Stanley
€4.46
Hold
51.74%
Upside
Reiterated
10/07/26
Analyst Maintains Hold Rating and $5 Price Target on Rocket Despite Long‑Term Danon Potential and Execution Risks
Leerink Partners Analyst forecast on DE:9IP1
Mani Foroohar
Leerink Partners
Leerink Partners
€6.25→€3.57
Hold
21.39%
Upside
Reiterated
10/07/26
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (NASDAQ: RCKT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Wedbush Analyst forecast on DE:9IP1
Yun Zhong
Wedbush
Wedbush
€13.38
Buy
355.21%
Upside
Reiterated
10/07/26
Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)
Cantor Fitzgerald Analyst forecast on DE:9IP1
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
€13.38
Buy
355.21%
Upside
Reiterated
10/06/26
Cantor Fitzgerald Remains a Buy on Rocket Pharmaceuticals (RCKT)
LifeSci Capital Analyst forecast on DE:9IP1
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€10.71
Buy
264.17%
Upside
Reiterated
10/02/26
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Chardan Capital Analyst forecast on DE:9IP1
Keay Nakae
Chardan Capital
Chardan Capital
€9.81
Buy
233.82%
Upside
Reiterated
09/15/26
Chardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
TD Cowen Analyst forecast on DE:9IP1
Tara Bancroft
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX) and Rocket Pharmaceuticals (NASDAQ: RCKT)
J.P. Morgan Analyst forecast on DE:9IP1
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
04/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (NASDAQ: RCKT) and Moderna (NASDAQ: MRNA)
Evercore ISI Analyst forecast on DE:9IP1
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€4.46
Hold
51.74%
Upside
Reiterated
12/17/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (NASDAQ: INSM), Novan (NASDAQ: NOVN) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rocket Pharmaceuticals

3 Months
Whitney IjemCanaccord Genuity
Success Rate
7/18 ratings generated profit
39%
Average Return
-12.92%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -12.92% per trade.
1 Year
Patrick DolezalLifeSci Capital
Success Rate
19/37 ratings generated profit
51%
Average Return
+3.84%
Copying Patrick Dolezal's trades and holding each position for 1 Year would result in 51.35% of your transactions generating a profit, with an average return of +3.84% per trade.
2 Years
Patrick DolezalLifeSci Capital
Success Rate
11/37 ratings generated profit
30%
Average Return
+7.83%
Copying Patrick Dolezal's trades and holding each position for 2 Years would result in 29.73% of your transactions generating a profit, with an average return of +7.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9IP1 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
9
6
9
13
19
Buy
0
0
0
0
0
Hold
3
2
4
6
9
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
8
13
19
28
In the current month, 9IP1 has received 19 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 9IP1 average Analyst price target in the past 3 months is 8.48.
Each month's total comprises the sum of three months' worth of ratings.

9IP1 Financial Forecast

9IP1 Earnings Forecast

Next quarter’s earnings estimate for 9IP1 is -€0.35 with a range of -€0.38 to -€0.27. The previous quarter’s EPS was €0.96. 9IP1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 9IP1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9IP1 is -€0.35 with a range of -€0.38 to -€0.27. The previous quarter’s EPS was €0.96. 9IP1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 9IP1 has Performed in-line its overall industry.
No data currently available

9IP1 Sales Forecast

Next quarter’s sales forecast for 9IP1 is €178.37K with a range of €0.00 to €1.78M. The previous quarter’s sales results were €0.00. 9IP1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 9IP1 has Performed in-line its overall industry.
Next quarter’s sales forecast for 9IP1 is €178.37K with a range of €0.00 to €1.78M. The previous quarter’s sales results were €0.00. 9IP1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 9IP1 has Performed in-line its overall industry.

9IP1 Stock Forecast FAQ

What is DE:9IP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is 8.48.
    What is DE:9IP1’s upside potential, based on the analysts’ average price target?
    Rocket Pharmaceuticals has 188.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Rocket Pharmaceuticals a Buy, Sell or Hold?
          Rocket Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Rocket Pharmaceuticals’s share price target?
            The average share price target for Rocket Pharmaceuticals is 8.48. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €13.38 ,and the lowest forecast is €3.57. The average share price target represents 188.30% Increase from the current price of €2.94.
              What do analysts say about Rocket Pharmaceuticals?
              Rocket Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Rocket Pharmaceuticals?
                To buy shares of DE:9IP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.